SCHEMBL25822107

SCHEMBL25822107

CC(C)C(=O)OC[C@@]1(F)O[C@@H](c2ccc3c(N)ncnn23)[C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ POLRMT O00411 1/20 0.38
▸ RIPK1 Q13546 7/20 0.32
▸ DOT1L Q8TEK3 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25822097 0.90 — —
SCHEMBL26230756 0.89 POLRMT (0.39) POLRMTRIPK1DOT1L
SCHEMBL25385857 0.85 POLRMT (0.37) POLRMTRIPK1DOT1L
SCHEMBL27439151 0.81 POLRMT (0.31) POLRMTRIPK1
SCHEMBL25822101 0.81 — —
SCHEMBL23803220 0.81 POLRMT (0.36) POLRMTRIPK1DOT1L
SCHEMBL23803201 0.81 POLRMT (0.37) POLRMTRIPK1DOT1L
SCHEMBL23803301 0.78 POLRMT (0.35) POLRMTRIPK1DOT1L
SCHEMBL31430648 0.78 POLRMT (0.35) POLRMT
SCHEMBL23844013 0.78 POLRMT (0.33) POLRMTRIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219993-A1 ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG VIGONVITA LIFE SCIENCES CO., LTD. (CN) 2023-07-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219993-A1 ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG PNP, TYMP, PIGS POLRMT 139/4885RIPK1 561/4885DOT1L 4360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback